Resistant hypertension (RH) is defined as above-goal elevated blood
pressure (BP) in a patient despite the concurrent use of 3 antihypertensive drug
classes, commonly including a long-acting calcium channel blocker, a blocker of
the renin-angiotensin system (angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker), and a diuretic. The antihypertensive drugs should
be administered at maximum or maximally tolerated daily doses. RH also includes
patients whose BP achieves target values on ≥4 antihypertensive
medications. The diagnosis of RH requires assurance of antihypertensive
medication adherence and exclusion of the “white-coat effect”
(office BP above goal but out-of-office BP at or below target). The importance
of RH is underscored by the associated risk of adverse outcomes compared with
non-RH. This article is an updated American Heart Association scientific
statement on the detection, evaluation, and management of RH. Once
antihypertensive medication adherence is confirmed and out-of-office BP
recordings exclude a white-coat effect, evaluation includes identification of
contributing lifestyle issues, detection of drugs interfering with
antihypertensive medication effectiveness, screening for secondary hypertension,
and assessment of target organ damage. Management of RH includes maximization of
lifestyle interventions, use of long-acting thiazide-like diuretics
(chlorthalidone or indapamide), addition of a mineralocorticoid receptor
antagonist (spironolactone or eplerenone), and, if BP remains elevated, stepwise
addition of antihypertensive drugs with complementary mechanisms of action to
lower BP. If BP remains uncontrolled, referral to a hypertension specialist is
advised.